SCM
PCRX icon

Southport Capital Management’s Pacira BioSciences PCRX Stock Holding History

Southport Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100
Closed -$3K – 361
2016
Q2 		$3K Buy
+100
New +$4.92K ﹤0.01% 491

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Southport Capital Management's PCRX Position: Q3 2016 in Review

Southport Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2016, closing a stake of 100 shares — an estimated $3K sold.

Southport Capital Management first reported a position in PCRX in Q2 2016 and held it in 1 quarter. The position peaked at $3K in Q2 2016. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

  • Southport Capital Management reported no remaining Pacira BioSciences position as of Q3 2016 after selling out during the quarter.
  • Southport Capital Management sold 100 Pacira BioSciences shares in Q3 2016, an estimated $3K.
  • Southport Capital Management first reported a position in Pacira BioSciences in Q2 2016 and held it in 1 quarter.
  • Southport Capital Management's Pacira BioSciences position peaked at $3K in Q2 2016.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on Southport Capital Management's 13F filing for Q3 2016, filed 19 Oct 2016.